1. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works
2. Under-Reporting of Adverse Drug Reactions
3. Guideline on good pharmacovigilance practices Module X—Additional monitoring. Retrieved from.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/04/WC500142282.pdf
4. Regulation (EC) No 726/2004 of the European Parliament and of the council of 31 March laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency Official Journal L–136 p. 1–33. Retrieved fromhttp://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0001:0033:en:PDF
5. Report from the Commission to the European Parliament and the Council on the national and European Medicines Agency experience regarding the list of medicines for human use subject to additional monitoring. Retrieved fromhttps://ec.europa.eu/transparency/regdoc/rep/1/2019/EN/COM-2019-591-F1-EN-MAIN-PART-1.PDF